{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:43:43Z","timestamp":1793447023786,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1053\/j.gastro.2022.11.034","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T08:20:12Z","timestamp":1673598012000},"page":"484-491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"title":["AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review"],"prefix":"10.1053","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3486-5494","authenticated-orcid":false,"given":"Bruce","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert L.","family":"Bonkovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Balwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2022.11.034_bib1","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1056\/NEJMra1608634","volume":"377","author":"Bissell","year":"2017","journal-title":"Porphyria. N Engl J Med"},{"issue":"9718","key":"10.1053\/j.gastro.2022.11.034_bib2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(09)61925-5","volume":"375","author":"Puy","year":"2010","journal-title":"Porphyrias. Lancet"},{"key":"10.1053\/j.gastro.2022.11.034_bib3","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/BF01481493","article-title":"New type of hepatic porphyria with porphobilinogen synthase defect and intermittent acute clinical manifestation","volume":"57","author":"Doss","year":"1979","journal-title":"Klin Wochenschr"},{"key":"10.1053\/j.gastro.2022.11.034_bib4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1023\/B:BOLI.0000037341.21975.9d","article-title":"The third case of Doss porphyria (delta-amino-levulinic acid dehydratase deficiency) in Germany","volume":"27","author":"Doss","year":"2004","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1053\/j.gastro.2022.11.034_bib5","first-page":"5","article-title":"Aminolaevulinate dehydratase porphyria in infancy. A clinical and biochemical study","volume":"25","author":"Thunell","year":"1987","journal-title":"J\u00a0Clin Chem Clin Biochem"},{"key":"10.1053\/j.gastro.2022.11.034_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ymgme.2005.10.011","article-title":"delta-Aminolevulinate dehydratase (ALAD) porphyria: the first case in North America with two novel ALAD mutations","volume":"87","author":"Akagi","year":"2006","journal-title":"Mol Genet Metab"},{"key":"10.1053\/j.gastro.2022.11.034_bib7","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/hmg\/ddy030","article-title":"From a dominant to an oligogenic model of inheritance with environmental modifiers in acute intermittent porphyria","volume":"27","author":"Lenglet","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1053\/j.gastro.2022.11.034_bib8","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/humu.23067","article-title":"Acute intermittent porphyria: predicted pathogenicity of HMBS variants indicates extremely low penetrance of the autosomal dominant disease","volume":"37","author":"Chen","year":"2016","journal-title":"Hum Mutat"},{"key":"10.1053\/j.gastro.2022.11.034_bib9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s13023-022-02463-x","article-title":"Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study","volume":"17","author":"Wang","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1053\/j.gastro.2022.11.034_bib10","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/hep.30936","article-title":"EXPLORE: a prospective, multinational, natural history study of patients with acute hepatic porphyria with recurrent attacks","volume":"71","author":"Gouya","year":"2020","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.11.034_bib11","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40271-018-0319-3","article-title":"Patient perspective on acute intermittent porphyria with frequent attacks: a disease with intermittent and chronic manifestations","volume":"11","author":"Simon","year":"2018","journal-title":"Patient"},{"key":"10.1053\/j.gastro.2022.11.034_bib12","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ymgme.2016.08.006","article-title":"Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: a qualitative study","volume":"119","author":"Naik","year":"2016","journal-title":"Mol Genet Metab"},{"key":"10.1053\/j.gastro.2022.11.034_bib13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ymgme.2018.10.001","article-title":"Hepatocellular carcinoma in acute hepatic porphyrias: a Damocles sword","volume":"128","author":"Peoc'h","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1053\/j.gastro.2022.11.034_bib14","first-page":"66","article-title":"Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes","volume":"55","author":"Sardh","year":"2009","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"10.1053\/j.gastro.2022.11.034_bib15","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/ki.2015.97","article-title":"High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria","volume":"88","author":"Pallet","year":"2015","journal-title":"Kidney Int"},{"key":"10.1053\/j.gastro.2022.11.034_bib16","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa1807838","article-title":"Phase 1 trial of an RNA interference therapy for acute intermittent porphyria","volume":"380","author":"Sardh","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2022.11.034_bib17","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s10545-012-9576-9","article-title":"High risk of primary liver cancer in a cohort of 179 patients with acute hepatic porphyria","volume":"36","author":"Sardh","year":"2013","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1053\/j.gastro.2022.11.034_bib18","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0168-8278(00)80097-5","article-title":"Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors","volume":"32","author":"Andant","year":"2000","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.11.034_bib19","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.amjmed.2014.06.036","article-title":"Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium","volume":"127","author":"Bonkovsky","year":"2014","journal-title":"Am J Med"},{"key":"10.1053\/j.gastro.2022.11.034_bib20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/00039896.1967.10664873","article-title":"Urinary delta-aminolevulinic acid (ALA) levels in lead poisoning. I. A modified method for the rapid determination of urinary delta-aminolevulinic acid using disposable ion-exchange chromatography columns","volume":"15","author":"Davis","year":"1967","journal-title":"Arch Environ Health"},{"key":"10.1053\/j.gastro.2022.11.034_bib21","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.jchromb.2011.06.034","article-title":"A\u00a0LC-MS\/MS method for the specific, sensitive, and simultaneous quantification of 5-aminolevulinic acid and porphobilinogen","volume":"879","author":"Zhang","year":"2011","journal-title":"J\u00a0Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1053\/j.gastro.2022.11.034_bib22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/bmc.2843","article-title":"Direct and simultaneous quantitation of 5-aminolaevulinic acid and porphobilinogen in human serum or plasma by hydrophilic interaction liquid chromatography-atmospheric pressure chemical ionization\/tandem mass spectrometry","volume":"27","author":"Benton","year":"2013","journal-title":"Biomed Chromatogr"},{"key":"10.1053\/j.gastro.2022.11.034_bib23","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/clinchem\/23.9.1666","article-title":"Comparison of the Hoesch and the Watson-Schwartz tests for urinary porphobilinogen","volume":"23","author":"Pierach","year":"1977","journal-title":"Clin Chem"},{"key":"10.1053\/j.gastro.2022.11.034_bib24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/jclinpath-2012-201367","article-title":"Urinary excretion of porphyrins, porphobilinogen and delta-aminolaevulinic acid following an attack of acute intermittent porphyria","volume":"67","author":"Marsden","year":"2014","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1053\/j.gastro.2022.11.034_bib25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2796.1995.tb01179.x","article-title":"Diagnosis of acute intermittent porphyria in northern Sweden: an evaluation of mutation analysis and biochemical methods","volume":"237","author":"Andersson","year":"1995","journal-title":"J\u00a0Intern Med"},{"key":"10.1053\/j.gastro.2022.11.034_bib26","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/clinchem\/48.11.1891","article-title":"Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families","volume":"48","author":"Kauppinen","year":"2002","journal-title":"Clin Chem"},{"key":"10.1053\/j.gastro.2022.11.034_bib27","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1373\/clinchem.2008.122564","article-title":"Diagnostic strategies for autosomal dominant acute porphyrias: retrospective analysis of 467 unrelated patients referred for mutational analysis of the HMBS, CPOX, or PPOX gene","volume":"55","author":"Whatley","year":"2009","journal-title":"Clin Chem"},{"key":"10.1053\/j.gastro.2022.11.034_bib28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/01.md.0000152454.56435.f3","article-title":"An analysis of 112 acute porphyric attacks in Cape Town, South Africa: evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity","volume":"84","author":"Hift","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.gastro.2022.11.034_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8278(88)80456-2","article-title":"Treatment of acute hepatic porphyria with hematin","volume":"6","author":"Bissell","year":"1988","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.11.034_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197001000-00001","article-title":"Acute intermittent porphyria. A clinical and biochemical study of 46 patients","volume":"49","author":"Stein","year":"1970","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.gastro.2022.11.034_bib31","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1073\/pnas.68.11.2725","article-title":"Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by intravenous infusions of hematin","volume":"68","author":"Bonkowsky","year":"1971","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2022.11.034_bib32","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00005792-197905000-00005","article-title":"Hematin therapy for acute porphyria","volume":"58","author":"Lamon","year":"1979","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.gastro.2022.11.034_bib33","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1073\/pnas.74.5.2118","article-title":"Postulated deficiency of hepatic heme and repair by hematin infusions in the \"inducible\" hepatic porphyrias","volume":"74","author":"Watson","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2022.11.034_bib34","doi-asserted-by":"crossref","first-page":"537","DOI":"10.7326\/0003-4819-144-7-200604040-00023","article-title":"Reconstitution of hematin for intravenous infusion","volume":"144","author":"Anderson","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2022.11.034_bib35","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.cell.2005.06.040","article-title":"Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha","volume":"122","author":"Handschin","year":"2005","journal-title":"Cell"},{"key":"10.1053\/j.gastro.2022.11.034_bib36","first-page":"89","article-title":"The acute porphyric attack. I. The electrolyte disorder of the acute porphyric attack and the possible role of delta-aminolaevulic acid","author":"Eales","year":"1971","journal-title":"S\u00a0Afr Med J"},{"key":"10.1053\/j.gastro.2022.11.034_bib37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1179\/acb.2008.051","article-title":"An unusual cause of syndrome of inappropriate antidiuretic hormone secretion","volume":"63","author":"Meersseman","year":"2008","journal-title":"Acta Clin Belg"},{"key":"10.1053\/j.gastro.2022.11.034_bib38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1212\/WNL.49.1.97","article-title":"Effects of new anticonvulsant medications on porphyrin synthesis in cultured liver cells: potential implications for patients with acute porphyria","volume":"49","author":"Hahn","year":"1997","journal-title":"Neurology"},{"key":"10.1053\/j.gastro.2022.11.034_bib39","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/hmg\/ddz003","article-title":"Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria","volume":"28","author":"Yasuda","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1053\/j.gastro.2022.11.034_bib40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13023-019-1031-7","article-title":"High penetrance of acute intermittent porphyria in a Spanish founder mutation population and CYP2D6 genotype as a susceptibility factor","volume":"14","author":"Barreda-Sanchez","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1053\/j.gastro.2022.11.034_bib41","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ymgme.2018.11.012","article-title":"Recent advances on porphyria genetics: inheritance, penetrance & molecular heterogeneity, including new modifying\/causative genes","volume":"128","author":"Yasuda","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1053\/j.gastro.2022.11.034_bib42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2119\/molmed.2015.00099","article-title":"Liver transplantation for acute intermittent porphyria: biochemical and pathologic studies of the explanted liver","volume":"21","author":"Yasuda","year":"2015","journal-title":"Mol Med"},{"key":"10.1053\/j.gastro.2022.11.034_bib43","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/joim.12750","article-title":"Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver","volume":"284","author":"Schmitt","year":"2018","journal-title":"J\u00a0Intern Med"},{"key":"10.1053\/j.gastro.2022.11.034_bib44","first-page":"99","article-title":"An audit of the use of gonadorelin analogues to prevent recurrent acute symptoms in patients with acute porphyria in the United Kingdom","volume":"36","author":"Schulenburg-Brand","year":"2017","journal-title":"JIMD Rep"},{"key":"10.1053\/j.gastro.2022.11.034_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.712305","article-title":"Prophylactic heme arginate infusion for acute intermittent porphyria","volume":"12","author":"Kuo","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1053\/j.gastro.2022.11.034_bib46","article-title":"Benefits of prophylactic heme therapy in severe acute intermittent porphyria","volume":"19","author":"Yarra","year":"2019","journal-title":"Mol Genet Metab Rep"},{"key":"10.1053\/j.gastro.2022.11.034_bib47","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2022.11.034_bib48","author":"US Food and Drug Administration"},{"key":"10.1053\/j.gastro.2022.11.034_bib49","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1038\/mtna.2015.36","article-title":"Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic porphyrias using circulating RNA quantification","volume":"4","author":"Chan","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1053\/j.gastro.2022.11.034_bib50","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.2147\/DDDT.S281631","article-title":"Spotlight on givosiran as a treatment option for adults with acute hepatic porphyria: design, development, and place in therapy","volume":"16","author":"Majeed","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1053\/j.gastro.2022.11.034_bib51","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/liv.15090","article-title":"Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study","volume":"42","author":"Ventura","year":"2022","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2022.11.034_bib52","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ymgme.2022.01.002","article-title":"Givosiran in acute intermittent porphyria: a personalized medicine approach","volume":"135","author":"Poli","year":"2022","journal-title":"Mol Genet Metab"},{"key":"10.1053\/j.gastro.2022.11.034_bib53","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/lt.22345","article-title":"Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis","volume":"18","author":"Dowman","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1053\/j.gastro.2022.11.034_bib54","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.27086","article-title":"Liver transplantation in the management of porphyria","volume":"60","author":"Singal","year":"2014","journal-title":"Hepatology"},{"issue":"9410","key":"10.1053\/j.gastro.2022.11.034_bib55","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(04)15646-8","article-title":"Liver transplantation as a cure for acute intermittent porphyria","volume":"363","author":"Soonawalla","year":"2004","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2022.11.034_bib56","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/lt.25959","article-title":"Liver transplantation for acute intermittent porphyria","volume":"27","author":"Lissing","year":"2021","journal-title":"Liver Transpl"},{"key":"10.1053\/j.gastro.2022.11.034_bib57","doi-asserted-by":"crossref","first-page":"904","DOI":"10.7326\/L18-0623","article-title":"Recurrence of acute intermittent porphyria after liver transplantation","volume":"170","author":"Al-Samkari","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2022.11.034_bib58","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1080\/00365510902935979","article-title":"Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study","volume":"69","author":"Bylesjo","year":"2009","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1053\/j.gastro.2022.11.034_bib59","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2796.2010.02335.x","article-title":"Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden","volume":"269","author":"Innala","year":"2011","journal-title":"J\u00a0Intern Med"},{"key":"10.1053\/j.gastro.2022.11.034_bib60","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/hep.29313","article-title":"Acute hepatic porphyrias: recommendations for evaluation and long-term management","volume":"66","author":"Balwani","year":"2017","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.11.034_bib61","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2796.1996.21847000.x","article-title":"The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria","volume":"240","author":"Andersson","year":"1996","journal-title":"J\u00a0Intern Med"},{"key":"10.1053\/j.gastro.2022.11.034_bib62","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/hep.31460","article-title":"Hepatocellular carcinoma in acute hepatic porphyrias: results from the longitudinal study of the U.S. Porphyrias Consortium","volume":"73","author":"Saberi","year":"2021","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.11.034_bib63","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/joim.13463","article-title":"Risk of primary liver cancer in acute hepatic porphyria patients: a matched cohort study of 1244 individuals","volume":"291","author":"Lissing","year":"2022","journal-title":"J\u00a0Intern Med"},{"key":"10.1053\/j.gastro.2022.11.034_bib64","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/joim.12646","article-title":"Acute hepatic porphyria and cancer risk: a nationwide cohort study","volume":"282","author":"Baravelli","year":"2017","journal-title":"J\u00a0Intern Med"},{"key":"10.1053\/j.gastro.2022.11.034_bib65","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/ckj\/sfx146","article-title":"Porphyria and kidney diseases","volume":"11","author":"Pallet","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1053\/j.gastro.2022.11.034_bib66","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1681\/ASN.2016080918","article-title":"A\u00a0variant of peptide transporter 2 predicts the severity of porphyria-associated kidney disease","volume":"28","author":"Tchernitchko","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.gastro.2022.11.034_bib67","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ekir.2021.04.004","article-title":"Renal function decline with small interfering RNA silencing aminolevulinic acid synthase 1 (ALAS1)","volume":"6","author":"Lazareth","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1053\/j.gastro.2022.11.034_bib68","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2020.08.004","article-title":"Kidney transplantation improves the clinical outcomes of acute intermittent porphyria","volume":"131","author":"Lazareth","year":"2020","journal-title":"Mol Genet Metab"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508522013567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508522013567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T15:40:08Z","timestamp":1758037208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508522013567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0016508522013567"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2022.11.034","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2022.11.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}